clinical trial · NCT07686068
First-in-Human Trial of VBC106 in Participants With Advanced Solid Tumors
VelaVigo Bio Inc·phase2·not yet recruiting·n = 260
Participants With Advanced Solid Tumor MalignanciesVBC106
brief summary
This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion adopts BOIN design to identify the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to confirm safety and tolerability and to further evaluate the efficacy of the selected RP2D in selected solid tumor malignancies for VBC106.
started
Aug 18, 2026
primary completion
Dec 1, 2028
completion
Dec 1, 2028
last updated
Jul 9, 2026
official title
Phase 1/2a Open-Label Clinical Trial Evaluating VBC106, an FRα- and MSLN-Directed Bispecific Antibody Drug Conjugate, in Participants With Advanced Malignant Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol